1. Anti-Wolbachia drugs for filariasis
- Author
-
W. David Hong, Stephen A. Ward, Paul M. O'Neill, Kelly L. Johnston, Mark J. Taylor, and Joseph D. Turner
- Subjects
Drug ,medicine.drug_class ,media_common.quotation_subject ,Antibiotics ,Onchocerciasis ,Bioinformatics ,Filariasis ,Elephantiasis, Filarial ,Drug Discovery ,medicine ,Humans ,Nematode Infections ,Lymphatic filariasis ,media_common ,biology ,business.industry ,Drug discovery ,medicine.disease ,biology.organism_classification ,Anti-Bacterial Agents ,Clinical trial ,Infectious Diseases ,Pharmacodynamics ,Parasitology ,Wolbachia ,business - Abstract
The mutualistic association between Wolbachia endosymbionts and their filarial nematode hosts has been exploited as a validated drug target delivering macrofilaricidal outcomes. Limitations of existing antibiotics to scale-up have driven the search for new drugs, which are effective in shorter regimens of 7 days or less. Here, we review the last 14 years of anti-Wolbachia drug discovery by the anti-Wolbachia (A·WOL) consortium, which has screened more than two million compounds, delivering thousands of hit compounds. Refined screening models integrated with robust pharmacokinetic/pharmacodynamic (PK/PD) driven optimisation and selection strategies have delivered the first two drug candidates specifically designed to target Wolbachia. AWZ1066S and ABBV-4083 are currently progressing through clinical trials with the aim of delivering safe and effective macrofilaricides to support the elimination of onchocerciasis and lymphatic filariasis.
- Published
- 2021
- Full Text
- View/download PDF